Contributions
Abstract: PB1631
Type: Publication Only
Background
Asparaginase is a component of a multi-agent chemotherapy regimen and is now a cornerstone treatment for patients with acute lymphoblastic leukemia (ALL). Since 2006, pegaspargase (PEG-ASP) has been the gold standard asparaginase for the treatment of pediatric ALL as it offers equivalent efficacy to native E. coli L-asparaginase (native ASP), with less frequent dosing, an IV administration option, and improved immunogenicity. Clinical outcomes in the adult ALL population are less well understood.
Aims
To assess the relative clinical benefit of PEG-ASP vs native ASP in 1st line treatment in newly diagnosed adult ALL patients in terms of event-free survival (EFS) and overall survival (OS). Safety outcomes were also examined.
Methods
A systematic literature search was conducted using a standardized search algorithm within the constraints of the National Library of Medicine database to identify available evidence for newly diagnosed patients treated with adult ALL protocols that use PEG-ASP or native ASP. Randomized, observational, and cohort studies were included, with the predefined clinical outcomes of event-free-survival (EFS) and overall survival (OS). Data was pooled with 95% confidence intervals (CIs) calculated using the logit transformation.
Results
A total of 30 studies were identified that met the pre-specified inclusion criteria, with 10 studies providing data for PEG-ASP and 23 studies for native ASP. The pooled estimate of 2-year EFS for adult ALL patients treated in 1st line with asparaginase was 48.0% (95% CI: [10.8; 85.2) for PEG-ASP and 66.0% (95% CI: [52.0; 77.0]) for native ASP.
Conclusion
The systematic literature review highlights a positive clinical effectiveness profile for PEG-ASP in regards to EFS and OS in the treatment of newly diagnosed adult ALL patients with less frequent administration and similar safety profile as compared with native ASP.
Session topic: 2. Acute lymphoblastic leukemia - Clinical
Keyword(s): Outcome, Asparaginase, adult, Acute lymphoblastic leukemia
Abstract: PB1631
Type: Publication Only
Background
Asparaginase is a component of a multi-agent chemotherapy regimen and is now a cornerstone treatment for patients with acute lymphoblastic leukemia (ALL). Since 2006, pegaspargase (PEG-ASP) has been the gold standard asparaginase for the treatment of pediatric ALL as it offers equivalent efficacy to native E. coli L-asparaginase (native ASP), with less frequent dosing, an IV administration option, and improved immunogenicity. Clinical outcomes in the adult ALL population are less well understood.
Aims
To assess the relative clinical benefit of PEG-ASP vs native ASP in 1st line treatment in newly diagnosed adult ALL patients in terms of event-free survival (EFS) and overall survival (OS). Safety outcomes were also examined.
Methods
A systematic literature search was conducted using a standardized search algorithm within the constraints of the National Library of Medicine database to identify available evidence for newly diagnosed patients treated with adult ALL protocols that use PEG-ASP or native ASP. Randomized, observational, and cohort studies were included, with the predefined clinical outcomes of event-free-survival (EFS) and overall survival (OS). Data was pooled with 95% confidence intervals (CIs) calculated using the logit transformation.
Results
A total of 30 studies were identified that met the pre-specified inclusion criteria, with 10 studies providing data for PEG-ASP and 23 studies for native ASP. The pooled estimate of 2-year EFS for adult ALL patients treated in 1st line with asparaginase was 48.0% (95% CI: [10.8; 85.2) for PEG-ASP and 66.0% (95% CI: [52.0; 77.0]) for native ASP.
Conclusion
The systematic literature review highlights a positive clinical effectiveness profile for PEG-ASP in regards to EFS and OS in the treatment of newly diagnosed adult ALL patients with less frequent administration and similar safety profile as compared with native ASP.
Session topic: 2. Acute lymphoblastic leukemia - Clinical
Keyword(s): Outcome, Asparaginase, adult, Acute lymphoblastic leukemia